Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PediFETCh: FMT for Pediatric UC and IBD-U
NCT02487238Phase 1Completed
- Sponsor
- McMaster Children's Hospital
- Start
- Nov 2015
- Primary completion
- Dec 2018
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of RBX2660 in ulcerative colitis (UC) and inflammatory bowel disease (IBD) (2 arms), sponsored by McMaster Children's Hospital. Primary endpoint: Feasibility (Composite Measure) at 30 weeks. Started Nov 2015; status: completed.
02
Drugs
RBX2660
03
Conditions
ulcerative colitis (UC)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT02487238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02487238.